Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracoronary adenosine during primary PCI for STEMI
IRCT20220809055645N6Phase 3Completed
- Sponsor
- Guilan University of Medical Sciences
- Start
- Jun 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of adenosine in acute ST-segment elevation myocardial infarction (STEMI) (2 arms), sponsored by Guilan University of Medical Sciences. Primary endpoint: Major adverse cardiac events. Started Jun 2023; status: completed.
02
Drugs
adenosine
03
Conditions
acute ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on IRCT20220809055645N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220809055645N6.